Harvard Heart Letter

New drug fizzles at raising HDL

With the failure of torcetrapib, a drug that its maker hoped would raise HDL cholesterol, people seeking to lower their heart disease risk should rely on traditional strategies: exercise, diet, weight control.

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In